- Author made OMDA a large position and believes it could 5x because its decade-plus evidence, data, payer relationships, integrations, and buyer trust are difficult to replicate.
- Omada sells covered chronic-care benefits through employers, health plans, and PBMs; those payers may promote enrollment because better outcomes could reduce healthcare costs, including GLP-1 coverage tied to enrollment.
- Existing payer channels let Omada convert eligible covered lives instead of acquiring every consumer through advertising, supporting more scalable CAC; the author acknowledges competitors such as Virta also have credible evidence.
Investment pitches
filter:
70